Huabo Biopharm Co., Ltd.   Report issue

For profit Phase 1
Founded: Shanghai China (2011)

Organization Overview

First Clinical Trial
2018
NCT03387566
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Huabo Biopharm Co., Ltd.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Macular Degeneration (Phase 1)

Neoplasms (Phase 1)

Wet Macular Degeneration (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 7
  • # of Trial APIs: 10